Lipid Sciences, Inc. (NASDAQ: LIPD) today announced that the Company had received notification from the Institutional Review Board (IRB) of Medstar Research Institute that approval had been given to begin a human clinical trial of Lipid Sciences’ Plasma Delipidation System-2 (PDS-2). With this approval, all conditions set by the FDA earlier this year have now been met for the initiation of the trial.
